CEN Case Reports

, Volume 7, Issue 1, pp 110–113 | Cite as

Capillary leak syndrome as a complication of antibody-mediated rejection treatment: a case report

  • Juan C. Ramirez-Sandoval
  • Ricardo Varela-Jimenez
  • Luis E. Morales-Buenrostro
Case Report


We report a case of capillary leak that developed during treatment of antibody-mediated rejection in a kidney transplant recipient. A 53-year-old female transplant recipient experienced an increase in serum creatinine from 1.1 to 1.8 mg/dL. Antibody-mediated rejection was diagnosed by graft biopsy. She was treated with five plasmapheresis sessions (on alternate days with albumin replacement), five doses of immunoglobulin (5 g/dose at 100 mg/kg), a single dose of rituximab (500 mg), and four doses of bortezomib on days 1, 4, 7, and 10 (1.72 mg/dose at 1.3 mg/m2 body surface area). During treatment, edema, slight diarrhea, pancytopenia, hypoalbuminemia, peripheral neuropathy, and postural hypotension were noted. Despite control of liquids, she presented with edema progressing to an increase of more than 10 kg body weight. Prerenal acute graft dysfunction associated with hypotension was diagnosed on day 12, heart failure or other infectious complications being discounted. On day 13, daily hemodialysis was prescribed, and a stable volume status was reached after five hemodialysis sessions. On day 20, the patient recovered diuresis and the edema and diarrhea abated, but she remained on chronic hemodialysis. After excluding other causes of distributive shock, the diagnosis of capillary leak syndrome was based on the presence of hypotension, generalized edema, and hypoalbuminemia in the absence of significant proteinuria. The concomitant presence of diarrhea, peripheral neuropathy, and pancytopenia, suggest a possible causal role for bortezomib. Awareness by clinicians of capillary leak syndrome associated with bortezomib-based treatment of AMR is paramount, despite its rarity.


Acute antibody-mediated rejection Proteasome inhibitor Graft failure Acute kidney injury Transplantation Clarkson disease 


Compliance with ethical standards

Conflict of interest

The authors have declared that no conflict of interest exists.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee at which the studies were conducted (IRB approval number SALUD-2006-C01-45085 for project: “Evaluación de la seguridad y eficacia del bortezomib en pacientes receptores de trasplante renal con rechazo agudo mediado por anticuerpos”) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.


  1. 1.
    Stegall MD, Dean PG, Gloor J. Mechanisms of alloantibody production in sensitized renal allograft recipients. Am J Transplant. 2009;9:998–1005.CrossRefPubMedGoogle Scholar
  2. 2.
    Sin Y-H, Kim Y-J, Oh JS, Lee JH, Kim SM, Kim JK. Treatment of acute antibody-mediated rejection using bortezomib: a case report. Nephrology. 2015;20:86–9.CrossRefPubMedGoogle Scholar
  3. 3.
    Kim M-G, Kim YJ, Kwon HY, Park HC, Koo TY, Jeong JC, et al. Outcomes of combination therapy for chronic antibody-mediated rejection in renal transplantation. Nephrology. 2013;18:820–6.CrossRefPubMedGoogle Scholar
  4. 4.
    Druey KM, Greipp PR. Narrative review: the systemic capillary leak syndrome. Ann Intern Med. 2010;153:90–8.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Levey AS, Stevens L, Schmid CH, Zhang YL, Castro AF, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–12.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Everly MJ, Everly JJ, Susskind B, Brailey P, Arend LJ, Alloway RR, et al. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation. 2008;86:1754–61.CrossRefPubMedGoogle Scholar
  7. 7.
    Schmidt N, Alloway RR, Walsh RC, Sadaka B, Shields AR, Girnita AL, et al. Prospective evaluation of the toxicity profile of proteasome inhibitor-based therapy in renal transplant candidates and recipients. Transplantation. 2012;94:352–61.CrossRefPubMedGoogle Scholar
  8. 8.
    Hsiao SC, Wang MC, Chang H, Pei SN. Recurrent capillary leak syndrome following bortezomib therapy in a patient with relapsed myeloma. Ann Pharmacother. 2010;44:587–9.CrossRefPubMedGoogle Scholar
  9. 9.
    Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239–45.CrossRefPubMedGoogle Scholar
  10. 10.
    Shi WY, Wang L, Xiao D, Yao Y, Yang F, Jiang XX, et al. Proteasome inhibitor bortezomib targeted tumor-endothelial cell interaction in T-cell leukemia/lymphoma. Ann Hematol. 2011;90:53–8.CrossRefPubMedGoogle Scholar
  11. 11.
    Eskandary F, Bond G, Schwaiger E, Kikic Z, Winzer C, Wahrmann M, et al. Bortezomib in late antibody-mediated kidney transplant rejection (BORTEJECT study): study protocol for a randomized controlled trial. Trials. 2014;15:107.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Leyva S, Marino L, Alberú J, Morales-Buenrostro LE. Bortezomib for acute humoral rejection treatment at the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán in Mexico City: an update. Clin Transpl. 2010;35:369–82.Google Scholar
  13. 13.
    Yang KS, Jeon H, Park Y, Jo IH, Kim J-I, Moon IS, et al. Use of bortezomib as anti-humoral therapy in kidney transplantation. J Korean Med Sci. 2014;29:648–51.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Japanese Society of Nephrology 2018

Authors and Affiliations

  • Juan C. Ramirez-Sandoval
    • 1
  • Ricardo Varela-Jimenez
    • 1
  • Luis E. Morales-Buenrostro
    • 1
  1. 1.Nephrology DepartmentNational Institute of Medical Sciences and Nutrition Salvador ZubiranMexico CityMexico

Personalised recommendations